CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Immunotherapy is an innovative type of cancer treatment that harnesses the patient's own immune system to recognize and eliminate cancer cells. In the last decade, the use of immunotherapy has increased exponentially, and it is now applied as the treatment of choice in many different cancer types. This popularity comes from the remarkable results seen in some patients treated with immunotherapy, which can lead to a cure in some cases and significantly prolong patient lives in others.
A new partnership between the Marathon of Hope Cancer Centres Network (MOHCCN) and the Canadian Clinical Trials Group (CCTG) will support three pan-Canadian research teams aiming to better understand how immunotherapies can best be used to increase survival, reduce toxicities and improve quality of life for cancer patients in Canada.
Melanoma is the deadliest form of skin cancer, and prior to 2010, outcomes were extremely poor for most patients with metastatic melanoma, where their cancer had spread to other parts of their body. Encouragingly, a class of treatments called immune checkpoint inhibitors (ICIs) dramatically improved survival for some patients, even leading to cures in some cases. However, some patients do not respond to ICI therapy and others experience severe side-effects.
The CCTG Patient Representative Committee is pleased to welcome Deb Clark who will support the Gynecologic Disease site committee. Deb lives in Regina and her journey began when her mom was diagnosed with ovarian cancer, now a 26-year cancer survivor. Deb supported her mom as her caregiver through three additional, primary cancers and was her husband’s caregiver when he had oral cancer.
